Description MUPS is abbreviation for Multiple-Unit Pellet System. However, from pharmaceutical industry and research perspective, the term in general refers to MUPS compacted into tablets. Thus, the resulting tablets prepared by compaction of modified release coated multiparticulates or pellets are called as MUPS.
The proton pump inhibitor Esomeprazole inhibits gastric acid by blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the proton pump) of the gastric parietal cell.
Esomeprazole MUPS tablets should be swallowed whole with liquid. The tablets should not be chewed or crushed.
Exium MUPS is extensively metabolized in the liver by CYP2C19 and CYP3A4. In vitro and in vivo studies have shown that Exium MUPS is not likely to inhibit CYPs 1A2, 2A6, 2C9, 2D6, 2E1 and 3A4.
Esomeprazole is contraindicated in patient with known hypersensitivity to any of the formulation.
The most frequently occurring adverse events reported with Exium MUPS include headache, diarrhoea, nausea, flatulence, abdominal pain, constipation and dry mouth. There are no difference in types of related adverse events seen during maintenance treatment upto 12 months compared to short term treatment.
The manufacturer advises caution. It is not known if Esomeprazole or its metabolites appear in human breast milk.
Exium MUPS should be used carefully if the patient has severe liver dysfunction and severe renal impairment. Taking a proton pump inhibitor like Exium MUPS may slightly increase the risk of hip, wrist and spine fracture, particularly when it is taken over a period of more than one year.
Store in a cool & dry place below 25ºC, protect from light. Keep out of reach of children.